Patents by Inventor J. Larry Jameson

J. Larry Jameson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus-mediated therapy for uterine fibroids
    Publication number: 20030199472
    Abstract: The present invention provides methods of treating and preventing uterine fibroids that is non-surgical, using a modified estrogen receptor gene delivered via an adenoviral vector. The modified estrogen receptor induced apoptosis in vitro and decreased tumor growth in vivo. The invention provides a major improvement above that of current available procedures for women having uterine fibroids, or in preventing fibroids in women at risk of having fibroids. The present invention further provides a safe means of treating fibroids and preserving fertility in young women, or maintaining pregnancy in pregnant women having fibroids.
    Type: Application
    Filed: March 19, 2003
    Publication date: October 23, 2003
    Applicants: Board of Regents, The University of Texas System, Northwestern University
    Inventors: Ayman Al-Hendy, Eun Jig Lee, J. Larry Jameson
  • Activin antagonists as novel contraceptives
    Patent number: 5824637
    Abstract: A method for contraception which features administering to a patient a contraceptive agent having activin-antagonist activity. The contraceptive agent results in inhibition of the activin-stimulated release of FSH, thereby resulting in a decrease in fertility and facilitating contraception in the patient.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: October 20, 1998
    Assignee: The General Hospital Corporation
    Inventors: William F. Crowley, J. Larry Jameson, Alan L. Schneyer, Jeffrey Weiss
  • Activin antagonists as novel contraceptives
    Patent number: 5658876
    Abstract: A method for contraception which features administering to a patient a contraceptive agent having activin-antagonist activity. The contraceptive agent results in inhibition of the activin-stimulated release of FSH, thereby resulting in a decrease in fertility and facilitating contraception in the patient.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: August 19, 1997
    Assignee: The General Hospital Corporation
    Inventors: William F. Crowley, J. Larry Jameson, Alan L. Schneyer, Jeffrey Weiss